Terns is developing a portfolio of small molecule product candidates in the oncology and obesity space. The pipeline contains three clinical-stage development programs, including an allosteric BCR-ABL ...
Good day, and thank you for standing by. Welcome to the Terns Pharmaceuticals TERN-701 December 2025 Data Update Conference Call. Please be advised that today's conference is being recorded. I would ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results